
Opinion|Videos|October 6, 2023
Clinical Biomarkers in Metastatic Breast Cancer
Author(s)Rebecca A. Shatsky, MD
A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5











































